Generally speaking, nuclear medicine is a specialty with both diagnostic and therapeutic uses.
The fundamental basis of nuclear medicine is the radiopharmaceutical – a drug which includes a radionuclide emitting radiation. The radiopharmaceutical is administered (orally or intravenously) to the patient and is then captured and retained in cells and tissues. The capacity of the radiopharmaceutical to locate specific organs and cell receptors allows it to supply information on the disease process based on cellular function and anatomy. The emissions from the radiopharmaceutical are received by external detectors, such as a gamma camera and camera PET, which are able to form images from the captured radiation.
At the CCC our mission is to utilise radiopharmaceuticals to provide the best possible service with a rapid response in all areas of diagnostic and therapeutic nuclear medicine. This includes General Nuclear Medicine, Single Photon Emission Tomography (SPECT), Positron Emission Tomography (PET), and therapy with radionuclides.
Our highly experienced team is involved in clinical research and active in a number of projects aimed at improving the quality of diagnostic and therapeutic nuclear medicine.